

REGISTERED NUMBER: 05272668 (England and Wales)

**GROUP STRATEGIC REPORT,
REPORT OF THE DIRECTORS AND
CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2021
FOR
MEDICAL MANAGEMENT SYSTEMS LIMITED**

THURSDAY



A08 *AB785XTZ* #49
30/06/2022
COMPANIES HOUSE

**CONTENTS OF THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2021**

	Page
Company Information	1
Group Strategic Report	2
Report of the Directors	3
Report of the Independent Auditors	5
Consolidated Statement of Profit or Loss and Other Comprehensive Income	9
Consolidated Statement of Financial Position	10
Company Statement of Financial Position	12
Consolidated Statement of Changes in Equity	14
Company Statement of Changes in Equity	15
Consolidated Statement of Cash Flows	16
Notes to the Consolidated Statement of Cash Flows	17
Notes to the Consolidated Financial Statements	18

MEDICAL MANAGEMENT SYSTEMS LIMITED

**COMPANY INFORMATION
FOR THE YEAR ENDED 30 SEPTEMBER 2021**

DIRECTORS:

P Louth
H Noshirvani
W G L Temple
S L Temple
D W A L Temple
A K Wolman

SECRETARY:

P Shepherd

REGISTERED OFFICE:

4th Floor
4 Crown Place
London
EC2A 4BT

REGISTERED NUMBER:

05272668 (England and Wales)

AUDITORS:

Haines Watts, Statutory Auditor
Chartered Accountants
Advantage
87 Castle Street
Reading
Berkshire
RG1 7SN

**GROUP STRATEGIC REPORT
FOR THE YEAR ENDED 30 SEPTEMBER 2021**

The directors present their strategic report of the Company and the Group for the year ended 30 September 2021.

REVIEW OF BUSINESS

The Group is focussed on the growth of recurring revenue and achieved a year on year growth of 23% to £5.6m in 2021. The directors are seeking to continue growing the business by focussing on innovative solutions, deeper customer relationships and enhancing operational capacity. EBITDA for 2021 decreased from £190k to an EBITDA loss of £19k as the group invested in staff to meet its future growth objectives.

PRINCIPAL RISKS AND UNCERTAINTIES

The Group has adopted a risk adverse approach to its trading activities by maintaining significant liquid balances. As such, in the short term, no particular risks are considered to be fundamental to the business. The directors continuously review internal and external threats to the business and the wider industry.

FINANCIAL KEY PERFORMANCE INDICATORS

The Group considers its key performance indicators to be long term growth in recurring revenue and EBITDA and a move towards sustainable cash generation.

ON BEHALF OF THE BOARD:



D W A L Temple - Director

31 March 2022

**REPORT OF THE DIRECTORS
FOR THE YEAR ENDED 30 SEPTEMBER 2021**

The directors present their report with the financial statements of the Company and the Group for the year ended 30 September 2021.

PRINCIPAL ACTIVITY

The principal activity of the Group continued to be that of providing specialist IT and software services primarily relating to the access, connectivity and storage of electronic medical records of patients and healthcare related data and leasing of medical equipment.

DIVIDENDS

No dividends will be distributed for the year ended 30 September 2021.

DIRECTORS

The directors shown below have held office during the whole of the period from 1 October 2020 to the date of this report.

P Louth
H Noshirvani
W G L Temple
S L Temple
D W A L Temple
A K Wolman

FINANCIAL INSTRUMENTS

The Group's principal financial instruments during the year comprised cash, bank loans and various non-derivative financial instruments such as trade debtors and trade creditors that arise directly from its operations.

It is and has been throughout the year under review, the Group's policy that no trading in financial instruments be undertaken.

The Group uses financial instruments to manage financial and commercial risk wherever it is appropriate to do so. The main risks arising from the Group's financial instruments are interest rate risk, liquidity/cash flow risk and credit risk.

STATEMENT OF DIRECTORS' RESPONSIBILITIES

The directors are responsible for preparing the Group Strategic Report, the Report of the Directors and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with international accounting standards in conformity with the requirements of the Companies Act 2006. Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Company and the Group and of the profit or loss of the Group for that period. In preparing these financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the Company's and the Group's transactions and disclose with reasonable accuracy at any time the financial position of the Company and the Group and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Company and the Group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

MEDICAL MANAGEMENT SYSTEMS LIMITED (REGISTERED NUMBER: 05272668)

**REPORT OF THE DIRECTORS
FOR THE YEAR ENDED 30 SEPTEMBER 2021**

STATEMENT AS TO DISCLOSURE OF INFORMATION TO AUDITORS

So far as the directors are aware, there is no relevant audit information (as defined by Section 418 of the Companies Act 2006) of which the Group's auditors are unaware, and each director has taken all the steps that he or she ought to have taken as a director in order to make himself or herself aware of any relevant audit information and to establish that the Group's auditors are aware of that information.

AUDITORS

The auditors, Haines Watts, Statutory Auditor, will be proposed for re-appointment at the forthcoming Annual General Meeting.

ON BEHALF OF THE BOARD:



D W A L Temple - Director

31 March 2022

REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF MEDICAL MANAGEMENT SYSTEMS LIMITED

Opinion

We have audited the financial statements of Medical Management Systems Limited (the 'Parent Company') and its subsidiaries (the 'Group') for the year ended 30 September 2021 which comprise the Consolidated Statement of Profit or Loss and Other Comprehensive Income, the Consolidated , the Consolidated Statement of Financial Position, the Company Statement of Financial Position, the Consolidated Statement of Changes in Equity, the Company Statement of Changes in Equity, the Consolidated Statement of Cash Flows and Notes to the Consolidated Statement of Cash Flows, Notes to the Financial Statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and International Financial Reporting Standards (IFRSs) in conformity with the requirements of the Companies Act 2006.

In our opinion:

- the financial statements give a true and fair view of the state of the Group's and of the Parent Company's affairs as at 30 September 2021 and of the Group's loss for the year then ended;
- the Group financial statements have been properly prepared in accordance with IFRSs in conformity with the requirements of the Companies Act 2006;
- the Parent Company financial statements have been properly prepared in accordance with IFRSs in conformity with the requirements of the Companies Act 2006 and as applied in accordance with the provisions of the Companies Act 2006; and
- the financial statements have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the Group in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group's and the parent company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

However, not all future events or conditions can be predicted. The COVID-19 viral pandemic is one of the most significant economic events for the UK with unprecedented levels of uncertainty of outcomes. It is therefore difficult to evaluate all of the potential implications on the company's trade, customers, suppliers and wider economy. The Directors' view on the impact of COVID-19 is disclosed in the accounting policy note on Going Concern.

REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF MEDICAL MANAGEMENT SYSTEMS LIMITED

Other information

The directors are responsible for the other information. The other information comprises the information in the Group Strategic Report and the Report of the Directors, but does not include the financial statements and our Report of the Auditors thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the Group Strategic Report and the Report of the Directors for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Group Strategic Report and the Report of the Directors have been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the group and the parent company and its environment obtained in the course of the audit, we have not identified material misstatements in the Group Strategic Report or the Report of the Directors.

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept by the parent company, or returns adequate for our audit have not been received from branches not visited by us; or
- the parent company financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of directors' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

Other matter

The Company did not require an audit for the year ended 30 September 2020. The corresponding figures are therefore unaudited.

Responsibilities of directors

As explained more fully in the Statement of Directors' Responsibilities set out on page three, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the group's and the parent company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the group or the parent company or to cease operations, or have no realistic alternative but to do so.

REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF MEDICAL MANAGEMENT SYSTEMS LIMITED

Auditors' responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

We obtained an understanding of the legal and regulatory framework applicable to the Company and the industry in which it operates. We determined that the following laws and regulations were most significant: IFRS - the International Financial Reporting Standard, the Companies Act 2006, ISO 27001, the Data Protection Act 2018 and relevant tax compliance regulations in the UK.

We obtained an understanding of how the Company is complying with those legal and regulatory frameworks by making enquiries of management.

We assessed the susceptibility of the company's financial statements to material misstatement, including how fraud might occur, by meeting with management to understand where management considered there was susceptibility to fraud. Audit procedures performed by the audit team included:

- Challenging assumptions and judgements made by management in its significant accounting estimates;
- Identifying and testing journal entries, with a focus on entries made with unusual accounting combinations;
- Confirming with management whether they have knowledge of any actual, suspected or illegal fraud;
- Evaluating whether there was evidence of bias by management that represents a risk of material misstatement due to fraud.

These procedures were designed to provide reasonable assurance that the financial statements were free from fraud or error.

Owing to the inherent limitations of an audit, there is an unavoidable risk that we may not have detected some material misstatements in the financial statements, even though we have properly planned and performed our audit in accordance with auditing standards. For example, the further removed non-compliance with laws and regulations (irregularities) is from the events and transactions reflected in the financial statements, the less likely the inherently limited procedures required by auditing standards would identify it. In addition, as with any audit, there remained a higher risk of non-detection of irregularities, as these may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal controls. We are not responsible for preventing non-compliance and cannot be expected to detect non-compliance with all laws and regulations.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our Report of the Auditors.

**REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF
MEDICAL MANAGEMENT SYSTEMS LIMITED**

Use of our report

This report is made solely to the Company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the Company's members those matters we are required to state to them in a Report of the Auditors and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Company and the Company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Haines Watts

Peter Wright Bsc FCA (Senior Statutory Auditor)
for and on behalf of Haines Watts, Statutory Auditor
Chartered Accountants
Advantage
87 Castle Street
Reading
Berkshire
RG1 7SN

Date: *31 March 2022*

MEDICAL MANAGEMENT SYSTEMS LIMITED (REGISTERED NUMBER: 05272668)

**CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME
FOR THE YEAR ENDED 30 SEPTEMBER 2021**

	Notes	2021 £	2020 as restated £
CONTINUING OPERATIONS			
Revenue	4	5,615,463	4,563,539
Cost of sales		<u>(716,350)</u>	<u>(148,380)</u>
GROSS PROFIT		4,899,113	4,415,159
Other operating income		1,453	1,739
Administrative expenses		<u>(5,380,784)</u>	<u>(4,586,121)</u>
OPERATING LOSS BEFORE EXCEPTIONAL ITEMS		(480,218)	(169,223)
Exceptional items	6	<u>-</u>	<u>(63,056)</u>
OPERATING LOSS		(480,218)	(232,279)
Finance costs	7	(49,822)	(16,256)
Finance income	7	<u>51,252</u>	<u>40,693</u>
LOSS BEFORE INCOME TAX	8	(478,788)	(207,842)
Income tax	9	<u>100,525</u>	<u>14,630</u>
LOSS FOR THE YEAR		(378,263)	(193,212)
OTHER COMPREHENSIVE INCOME		<u>-</u>	<u>-</u>
TOTAL COMPREHENSIVE INCOME FOR THE YEAR		(378,263)	<u>(193,212)</u>
Prior year adjustment	11	<u>(52,143)</u>	
TOTAL COMPREHENSIVE INCOME SINCE LAST ANNUAL REPORT		<u>(430,406)</u>	
Loss attributable to: Owners of the parent		<u>(378,263)</u>	<u>(193,212)</u>
Total comprehensive income attributable to: Owners of the parent		<u>(430,406)</u>	<u>(193,212)</u>

The notes form part of these financial statements

MEDICAL MANAGEMENT SYSTEMS LIMITED (REGISTERED NUMBER: 05272668)

**CONSOLIDATED STATEMENT OF FINANCIAL POSITION
30 SEPTEMBER 2021**

	Notes	2021 £	2020 as restated £
ASSETS			
NON-CURRENT ASSETS			
Owned			
Intangible assets	12	959,109	747,420
Property, plant and equipment	13	103,790	164,355
Right-of-use			
Property, plant and equipment	13, 22	37,142	292,273
Investments	14	-	-
		<u>1,100,041</u>	<u>1,204,048</u>
CURRENT ASSETS			
Inventories	15	24,796	-
Trade and other receivables	16	1,643,176	1,648,879
Tax receivable		100,525	14,630
Cash and cash equivalents	17	3,971,056	2,458,121
		<u>5,739,553</u>	<u>4,121,630</u>
TOTAL ASSETS		<u>6,839,594</u>	<u>5,325,678</u>
EQUITY			
SHAREHOLDERS' EQUITY			
Called up share capital	18	1,412	1,412
Share premium	19	2,946,853	2,946,853
Retained earnings	19	(407,774)	(29,511)
TOTAL EQUITY		<u>2,540,491</u>	<u>2,918,754</u>
LIABILITIES			
NON-CURRENT LIABILITIES			
Financial liabilities - borrowings			
Interest bearing loans and borrowings	21	1,837,553	111,258
CURRENT LIABILITIES			
Trade and other payables	20	2,062,469	2,105,375
Financial liabilities - borrowings			
Interest bearing loans and borrowings	21	399,081	190,291
		<u>2,461,550</u>	<u>2,295,666</u>
TOTAL LIABILITIES		<u>4,299,103</u>	<u>2,406,924</u>
TOTAL EQUITY AND LIABILITIES		<u>6,839,594</u>	<u>5,325,678</u>

The financial statements were approved and authorised for issue by the Board of Directors and authorised for issue on 31 March 2022 and were signed on its behalf by:

The notes form part of these financial statements

MEDICAL MANAGEMENT SYSTEMS LIMITED (REGISTERED NUMBER: 05272668)

CONSOLIDATED STATEMENT OF FINANCIAL POSITION - continued
30 SEPTEMBER 2021



D W A L Temple - Director

The notes form part of these financial statements

MEDICAL MANAGEMENT SYSTEMS LIMITED (REGISTERED NUMBER: 05272668)

**COMPANY STATEMENT OF FINANCIAL POSITION
30 SEPTEMBER 2021**

	Notes	2021 £	2020 as restated £
ASSETS			
NON-CURRENT ASSETS			
Owned			
Intangible assets	12	959,109	747,420
Property, plant and equipment	13	83,290	164,355
Right-of-use			
Property, plant and equipment	13, 22	37,142	292,273
Investments	14	1	-
		<u>1,079,542</u>	<u>1,204,048</u>
CURRENT ASSETS			
Trade and other receivables	16	1,541,860	1,648,879
Tax receivable		100,525	14,630
Cash and cash equivalents	17	3,829,059	2,458,121
		<u>5,471,444</u>	<u>4,121,630</u>
TOTAL ASSETS		<u>6,550,986</u>	<u>5,325,678</u>
EQUITY			
SHAREHOLDERS' EQUITY			
Called up share capital	18	1,412	1,412
Share premium	19	2,946,853	2,946,853
Retained earnings	19	(756,874)	(29,511)
TOTAL EQUITY		<u>2,191,391</u>	<u>2,918,754</u>
LIABILITIES			
NON-CURRENT LIABILITIES			
Financial liabilities - borrowings			
Interest bearing loans and borrowings	21	1,837,553	111,258
CURRENT LIABILITIES			
Trade and other payables	20	2,122,961	2,105,375
Financial liabilities - borrowings			
Interest bearing loans and borrowings	21	399,081	190,291
		<u>2,522,042</u>	<u>2,295,666</u>
TOTAL LIABILITIES		<u>4,359,595</u>	<u>2,406,924</u>
TOTAL EQUITY AND LIABILITIES		<u>6,550,986</u>	<u>5,325,678</u>

The financial statements were approved and authorised for issue by the Board of Directors and authorised for issue on 31 March 2022 and were signed on its behalf by:

The notes form part of these financial statements

MEDICAL MANAGEMENT SYSTEMS LIMITED (REGISTERED NUMBER: 05272668)

COMPANY STATEMENT OF FINANCIAL POSITION - continued
30 SEPTEMBER 2021



D W A L Temple - Director

The notes form part of these financial statements

MEDICAL MANAGEMENT SYSTEMS LIMITED (REGISTERED NUMBER: 05272668)

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 30 SEPTEMBER 2021

	Called up share capital £	Retained earnings £	Share premium £	Total equity £
Balance at 1 October 2019	1,412	163,701	2,946,853	3,111,966
Changes in equity				
Total comprehensive income	-	(141,069)	-	(141,069)
Balance at 30 September 2020	<u>1,412</u>	<u>22,632</u>	<u>2,946,853</u>	<u>2,970,897</u>
Prior year adjustment	-	(52,143)	-	(52,143)
As restated	<u>1,412</u>	<u>(29,511)</u>	<u>2,946,853</u>	<u>2,918,754</u>
Changes in equity				
Total comprehensive income	-	(378,263)	-	(378,263)
Balance at 30 September 2021	<u>1,412</u>	<u>(407,774)</u>	<u>2,946,853</u>	<u>2,540,491</u>

The notes form part of these financial statements

MEDICAL MANAGEMENT SYSTEMS LIMITED (REGISTERED NUMBER: 05272668)

COMPANY STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 30 SEPTEMBER 2021

	Called up share capital £	Retained earnings £	Share premium £	Total equity £
Balance at 1 October 2019	1,412	163,701	2,946,853	3,111,966
Changes in equity				
Total comprehensive income	<u>-</u>	<u>(141,069)</u>	<u>-</u>	<u>(141,069)</u>
Balance at 30 September 2020	<u>1,412</u>	<u>22,632</u>	<u>2,946,853</u>	<u>2,970,897</u>
Prior year adjustment	<u>-</u>	<u>(52,143)</u>	<u>-</u>	<u>(52,143)</u>
As restated	<u>1,412</u>	<u>(29,511)</u>	<u>2,946,853</u>	<u>2,918,754</u>
Changes in equity				
Total comprehensive income	<u>-</u>	<u>(727,363)</u>	<u>-</u>	<u>(727,363)</u>
Balance at 30 September 2021	<u>1,412</u>	<u>(756,874)</u>	<u>2,946,853</u>	<u>2,191,391</u>

The notes form part of these financial statements

MEDICAL MANAGEMENT SYSTEMS LIMITED (REGISTERED NUMBER: 05272668)

CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 30 SEPTEMBER 2021

	Notes	2021 £	2020 as restated £
Cash flows from operating activities			
Cash generated from operations	1	(56,223)	(1,121,417)
Lease interest paid		(9,089)	(16,256)
Tax paid		14,630	-
Net cash from operating activities		<u>(50,682)</u>	<u>(1,137,673)</u>
Cash flows from investing activities			
Purchase of intangible fixed assets		(279,175)	(404,939)
Purchase of tangible fixed assets		(136,880)	(170,383)
Interest received		-	10,663
Net cash from investing activities		<u>(416,055)</u>	<u>(564,659)</u>
Cash flows from financing activities			
New loans in year		2,216,250	-
Payment of lease liabilities		(236,578)	(221,124)
Net cash from financing activities		<u>1,979,672</u>	<u>(221,124)</u>
Increase/(decrease) in cash and cash equivalents			
Cash and cash equivalents at beginning of year	2	2,458,121	4,381,577
Cash and cash equivalents at end of year	2	<u>3,971,056</u>	<u>2,458,121</u>

The notes form part of these financial statements

NOTES TO THE CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 30 SEPTEMBER 2021

1. RECONCILIATION OF LOSS BEFORE INCOME TAX TO CASH GENERATED FROM OPERATIONS

	2021	2020 as restated
	£	£
Loss before income tax	(478,788)	(207,842)
Depreciation charges	425,895	343,469
Loss on disposal of fixed assets	8,849	-
Gain on reduction in lease term	(22,429)	-
Finance costs	49,822	16,256
Finance income	(51,252)	(40,693)
	<u>(67,903)</u>	111,190
Increase in inventories	(24,796)	-
Increase in trade and other receivables	(292,339)	(462,505)
Increase/(decrease) in trade and other payables	<u>328,815</u>	<u>(770,102)</u>
Cash generated from operations	<u>(56,223)</u>	<u>(1,121,417)</u>

2. CASH AND CASH EQUIVALENTS

The amounts disclosed on the Statement of Cash Flows in respect of cash and cash equivalents are in respect of these Statement of Financial Position amounts:

Year ended 30 September 2021

	30/9/21	1/10/20
	£	£
Cash and cash equivalents	<u>3,971,056</u>	<u>2,458,121</u>

Year ended 30 September 2020

	30/9/20	1/10/19 as restated
	£	£
Cash and cash equivalents	<u>2,458,121</u>	<u>4,381,577</u>

The notes form part of these financial statements

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2021

1. STATUTORY INFORMATION

Medical Management Systems Limited is a private company, limited by shares, registered in England and Wales. The company's registered number and registered office address can be found on the General Information page.

The presentation currency of the financial statements is the Pound Sterling (£).

2. ACCOUNTING POLICIES

Basis of preparation

Compliance with IFRS

The consolidated financial statements of the Medical Management Systems Limited group have been prepared in accordance with international accounting standards in conformity with the requirements of the Companies Act 2006 and international financial reporting standards adopted pursuant to Regulation (EC) No 1606/2002 as it applies in the European Union.

Historical cost convention

The financial statements have been prepared on a historical cost basis, except for the revaluation of the assets and liabilities of the Group held in non-functional currencies.

New standards and interpretations not yet adopted

The following Adopted IFRSs have been issued but have not been applied by the Group in these financial statements. Their adoption is not expected to have a material effect on the financial statements unless otherwise indicated:

- IFRS 17 Insurance Contracts (effective date to be confirmed)
- IFRIC 22 Foreign Currency Transactions and Advance Consideration (effective date to be confirmed)
- IFRIC 23 Uncertainty over Income Tax Treatments (effective date to be confirmed)
- Annual Improvements to IFRS Standards 2014-2016 (effective date to be confirmed)
- Amendments to IAS 40: Transfers of Investment Property (effective date to be confirmed)
- Amendments to IAS 28: Long-term Interest in Associates and Joint Ventures (effective date to be confirmed)
- Amendments to IFRS 4: Applying IFRS 4: Applying IFRS 9 Financial Instruments with IFRS 4 Insurance Contracts (effective date to be confirmed)
- Amendments to IFRS 9: Prepayment Features with Negative Compensation (effective date to be confirmed)
- Amendments to IFRS 2: Classification and Measurement of Share-based Payment Transactions (effective date to be confirmed)

Basis of consolidation

The consolidated financial statements present the results of the Group and its own subsidiaries ("the Group") as if they form a single entity. Intercompany transactions and balances between group companies are therefore eliminated in full.

Going concern

The directors have at the time of approving the financial statements, a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 30 SEPTEMBER 2021

2. ACCOUNTING POLICIES - continued

Revenue recognition

Revenue is split between recurring and non-recurring product or service lines. Revenue is measured based on the transactional price that is determined from the contractual consideration with the customer.

The entity recognises the revenue on transfer of control to a customer at the point the service becomes available to the customer for use. Contractual licence revenue is recognised over the term in which the service is delivered by the entity and consumed by the customer.

Revenue is shown net of any rebates, returns or expected cash out flows.

For standard 'off-the-shelf' sales, revenue is recognised as the value of consideration assigned.

For those contracts which are bespoke and cannot feasibly be repurposed, revenue is recognised as a single performance obligation or duty. The measurement of revenue in fulfilment of the contract is based on the entity's inputs against budgeted cost to deliver the contract.

Timing differences arising due to non-coterminous payment terms and revenue recognition are either accrued or deferred. Where this is substantial and can be seen to represent a financing arrangement, they will be held at fair value. Any interest is released to the Income Statement as a financing item.

Cash and cash equivalents

Cash represents cash in hand and deposits held on demand with financial institutions. Cash equivalents are short-term, highly-liquid investments with original maturities of three months or less (as at their date of acquisition). Cash equivalents are readily convertible to known amounts of cash and subject to an insignificant risk of change in that cash value.

In the presentation of the Statement of Cash Flows, cash and cash equivalents also include bank overdrafts. Any such overdrafts are shown within borrowings under 'current liabilities' on the Statement of Financial Position.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 30 SEPTEMBER 2021

2. ACCOUNTING POLICIES - continued

Intangible assets

Intangible assets acquired separately from a business are recognised at cost and are subsequently measured at cost less accumulated amortisation and accumulated impairment losses.

Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following basis:

Development costs	- 10 years straight line
Capitalised software	- 3 years straight line

Property, plant and equipment

Property, plant and equipment are initially measured at cost and subsequently measured at cost net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following basis:

Fixtures & fittings	- 20% reducing balance
Plant & machinery	- 3 years straight line

Impairment of tangible and intangible assets

At each reporting end date, the Company reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the Company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 30 SEPTEMBER 2021

2. ACCOUNTING POLICIES - continued

Financial assets

Non-derivative financial instruments

Non-derivative financial instruments comprise investments in equity and debt securities, trade and other receivables, cash and cash equivalents, loans and borrowings, and trade and other payables.

Trade and other receivables:

Trade receivables are measured at amortised cost using the effective interest method, less any allowance for expected credit losses. When assessing recoverability the Directors consider the aging of receivables, past experience of recoverability, and the credit profile of individuals or Companies when calculating a provision for expected credit loss. Provisions for expected credit losses are measured at each reporting date.

Trade and other payables:

Trade and other payables are recognised initially at fair value. Subsequent to initial recognition they are measured at amortised cost using the effective interest method.

Cash and cash equivalents:

Cash and cash equivalents comprise cash balances and call deposits. Bank overdrafts that are repayable on demand and form an integral part of the Group's cash management are included as a component of cash and cash equivalents for the purpose only of the cash flow statement.

Interest-bearing borrowings:

Interest-bearing borrowings are recognised initially at fair value less attributable transaction costs. Subsequent to initial recognition, interest-bearing borrowings are stated at amortised cost using the effective interest method, less any impairment losses.

Financial assets

Trade debtors:

Trade debtors which are receivable within one year and which do not constitute a financing transaction are initially measured at the transaction price. Trade debtors are subsequently measured at amortised cost, being the transaction price less any amounts settled and any impairment losses.

Where the arrangement with a trade debtor constitutes a financing transaction, the debtor is initially and subsequently measured at the present value of future payments discounted at a market rate of interest for a similar debt instrument.

A provision for impairment of trade debtors is established when there is objective evidence that the amounts due will not be collected according to the original terms of the contract. Impairment losses are recognised in profit or loss for the excess of the carrying value of the trade debtor over the present value of the future cash flows discounted using the original effective interest rate. Subsequent reversals of an impairment loss that objectively relate to an event occurring after the impairment loss was recognised, are recognised immediately in profit or loss.

Trade receivables are measured at amortised cost using the effective interest method, less any allowance for expected credit losses. Expected credit losses are measured at each reporting date following a risk based and ageing based probability-weighted estimate of the potential credit loss.

Financial liabilities and equity

Financial instruments are classified as liabilities and equity instruments according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the Group after deducting all of its liabilities.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 30 SEPTEMBER 2021

2. ACCOUNTING POLICIES - continued

Equity instruments:

Financial instruments classified as equity instruments are recorded at the fair value of the cash or other resources received or receivable, net of direct costs of issuing the equity instruments.

Trade creditors:

Trade creditors payable within one year that do not constitute a financing transaction are initially measured at the transaction price and subsequently measured at amortised cost, being the transaction price less any amounts settled.

Where the arrangement with a trade creditor constitutes a financing transaction, the creditor is initially and subsequently measured at the present value of future payments discounted at a market rate of interest for a similar instrument.

Borrowings:

Borrowings are initially recognised at the transaction price, including transaction costs, and subsequently measured at amortised cost using the effective interest method. Interest expense is recognised on the basis of the effective interest method and is included in interest payable and other similar charges.

Derecognition of financial assets and liabilities:

A financial asset is derecognised only when the contractual rights to cash flows expire or are settled, or substantially all the risks and rewards of ownership are transferred to another party, or if some significant risks and rewards of ownership are retained but control of the asset has transferred to another party that is able to sell the asset in its entirety to an unrelated third party. A financial liability (or part thereof) is derecognised when the obligation specified in the contract is discharged, cancelled or expires.

Taxation

Current taxes are based on the results shown in the financial statements and are calculated according to local tax rules, using tax rates enacted or substantially enacted by the statement of financial position date.

Foreign currencies

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

Leases

Leases are recognised as finance leases. The lease liability is initially recognised at the present value of the lease payments which have not yet been made and subsequently measured under the amortised cost method. The initial cost of the right-of-use asset comprises the amount of the initial measurement of the lease liability, lease payments made prior to the lease commencement date, initial direct costs and the estimated costs of removing or dismantling the underlying asset per the conditions of the contract.

Where ownership of the right-of-use asset transfers to the lessee at the end of the lease term, the right-of-use asset is depreciated over the asset's remaining useful life. If ownership of the right-of-use asset does not transfer to the lessee at the end of the lease term, depreciation is charged over the shorter of the useful life of the right-of-use asset and the lease term.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 30 SEPTEMBER 2021

2. ACCOUNTING POLICIES - continued

Defined contribution plans

A defined contribution plan is a post-employment benefit plan under which an entity pays fixed contributions into a separate entity and will have no legal or constructive obligation to pay further amounts. The Company and its subsidiaries in various geographies make contributions, generally determined as a specified percentage of employee salaries, in respect of qualifying employees in accordance with the local laws and regulations in the respective countries which are defined contribution plans. Obligations for contributions to defined contribution plans are recognised as an employee benefit expense in profit or loss in the periods during which the related services are rendered by employees.

Employee benefit costs

The costs of short-term employee benefits are recognised as a liability and an expense. The best estimate of the expenditure required to settle an obligation for termination benefits is recognised immediately as an expense when the Group is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

3. CRITICAL ACCOUNTING JUDGEMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY

In preparing these financial statements, management has made judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised prospectively.

4. REVENUE

Segmental reporting

In presenting the geographical information, segment revenue has been based on the geographic location of customer.

	2021	2020 as restated
	£	£
UK	5,518,920	4,560,653
Rest of World	<u>96,543</u>	<u>2,866</u>
	<u>5,615,463</u>	<u>4,563,519</u>

Revenue from contracts with customers

One customer does account for more than 10% of the revenue, however this has not been disclosed as it is considered commercially sensitive information.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 30 SEPTEMBER 2021

5. EMPLOYEES AND DIRECTORS

	2021	2020 as restated
	£	£
Wages and salaries	3,253,284	2,808,938
Social security costs	404,563	385,471
Other pension costs	<u>59,557</u>	<u>53,206</u>
	<u>3,717,404</u>	<u>3,247,615</u>

The average number of employees during the year was as follows:

	2021	2020 as restated
Directors and employees	<u>66</u>	<u>60</u>

	2021	2020 as restated
	£	£
Directors' remuneration	578,000	578,680
Directors' pension contributions to money purchase schemes	<u>2,634</u>	<u>2,629</u>

Information regarding the highest paid director is as follows:

	2021	2020 as restated
	£	£
Emoluments etc	200,000	200,000
Pension contributions to money purchase schemes	<u>1,317</u>	<u>1,315</u>

6. EXCEPTIONAL ITEMS

	2021	2020
	£	£
Holiday pay	<u>-</u>	<u>63,056</u>

7. NET FINANCE INCOME

	2021	2020 as restated
	£	£
Finance income:		
Deposit account interest	-	10,663
Other interest received	<u>51,252</u>	<u>30,030</u>
	<u>51,252</u>	<u>40,693</u>

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 30 SEPTEMBER 2021

7. NET FINANCE INCOME - continued

	2021	2020 as restated
	£	£
Finance costs:		
Bank interest	72	-
Loan	40,661	-
Leasing	<u>9,089</u>	<u>16,256</u>
	<u>49,822</u>	<u>16,256</u>
Net finance income	<u>1,430</u>	<u>24,437</u>

8. LOSS BEFORE INCOME TAX

The loss before income tax is stated after charging/(crediting):

	2021	2020 as restated
	£	£
Cost of inventories recognised as expense	716,350	148,380
Depreciation - owned assets	164,597	98,817
Depreciation - assets on finance leases	193,810	210,080
Loss on disposal of fixed assets	8,849	-
Development costs amortisation	67,486	34,572
Auditors' remuneration	15,000	-
Foreign exchange differences	49,090	15,397
Gain on reduction in lease term	<u>(22,429)</u>	<u>-</u>

9. INCOME TAX

Analysis of tax income

	2021	2020 as restated
	£	£
Current tax:		
Prior year tax	<u>(100,525)</u>	<u>(14,630)</u>
Total tax income in consolidated statement of profit or loss and other comprehensive income	<u>(100,525)</u>	<u>(14,630)</u>

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 30 SEPTEMBER 2021

9. INCOME TAX - continued

Factors affecting the tax expense

The tax assessed for the year is lower (2020 - higher) than the standard rate of corporation tax in the UK. The difference is explained below:

	2021	2020 as restated
	£	£
Loss before income tax	<u>(478,788)</u>	<u>(207,842)</u>
Loss multiplied by the standard rate of corporation tax in the UK of 19% (2020 - 19%)	(90,970)	(39,490)
Effects of:		
Expenditure not allowable	1,360	1,818
Depreciation in excess of allowance	2,382	26,310
Adjustment in respect of prior period	(100,525)	(14,630)
Other differences	581	11,362
Losses carried forward	<u>86,647</u>	-
Tax income	<u>(100,525)</u>	<u>(14,630)</u>

10. LOSS OF PARENT COMPANY

As permitted by Section 408 of the Companies Act 2006, the statement of comprehensive income of the parent company is not presented as part of these financial statements. The parent company's loss for the financial year was £(727,363) (2020 - £(193,212)).

11. PRIOR YEAR ADJUSTMENT

A prior year adjustment has been made to recognise additional staff costs.

Changes in profit and loss to 30 September 2020

Retained earnings have decreased by £52,143 as a result of the following adjustments:

Increase in staff costs	£
	<u>52,143</u>
	<u>52,143</u>

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 30 SEPTEMBER 2021

12. INTANGIBLE ASSETS

Group	Development costs £
COST	
At 1 October 2020	1,105,777
Additions	<u>279,175</u>
At 30 September 2021	<u>1,384,952</u>
AMORTISATION	
At 1 October 2020	358,357
Amortisation for year	<u>67,486</u>
At 30 September 2021	<u>425,843</u>
NET BOOK VALUE	
At 30 September 2021	<u>959,109</u>
At 30 September 2020	<u>747,420</u>
 Company	
	Development costs £
COST	
At 1 October 2020	1,105,777
Additions	<u>279,175</u>
At 30 September 2021	<u>1,384,952</u>
AMORTISATION	
At 1 October 2020	358,357
Amortisation for year	<u>67,486</u>
At 30 September 2021	<u>425,843</u>
NET BOOK VALUE	
At 30 September 2021	<u>959,109</u>
At 30 September 2020	<u>747,420</u>

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 30 SEPTEMBER 2021

13. PROPERTY, PLANT AND EQUIPMENT

Group	Short leasehold £	Plant and machinery £	Totals £
COST			
At 1 October 2020	586,722	399,536	986,258
Additions	24,000	112,880	136,880
Disposals	<u>(473,191)</u>	<u>(33,340)</u>	<u>(506,531)</u>
At 30 September 2021	<u>137,531</u>	<u>479,076</u>	<u>616,607</u>
DEPRECIATION			
At 1 October 2020	294,449	235,181	529,630
Charge for year	193,810	164,597	358,407
Eliminated on disposal	<u>(387,870)</u>	<u>(24,492)</u>	<u>(412,362)</u>
At 30 September 2021	<u>100,389</u>	<u>375,286</u>	<u>475,675</u>
NET BOOK VALUE			
At 30 September 2021	<u>37,142</u>	<u>103,790</u>	<u>140,932</u>
At 30 September 2020	<u>292,273</u>	<u>164,355</u>	<u>456,628</u>
Company			
	Short leasehold £	Plant and machinery £	Totals £
COST			
At 1 October 2020	586,722	399,536	986,258
Additions	24,000	46,880	70,880
Disposals	<u>(473,191)</u>	<u>(33,340)</u>	<u>(506,531)</u>
At 30 September 2021	<u>137,531</u>	<u>413,076</u>	<u>550,607</u>
DEPRECIATION			
At 1 October 2020	294,449	235,181	529,630
Charge for year	193,810	119,097	312,907
Eliminated on disposal	<u>(387,870)</u>	<u>(24,492)</u>	<u>(412,362)</u>
At 30 September 2021	<u>100,389</u>	<u>329,786</u>	<u>430,175</u>
NET BOOK VALUE			
At 30 September 2021	<u>37,142</u>	<u>83,290</u>	<u>120,432</u>
At 30 September 2020	<u>292,273</u>	<u>164,355</u>	<u>456,628</u>

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 30 SEPTEMBER 2021

14. INVESTMENTS

Company

	Shares in group undertakings £
COST	
Additions	<u>1</u>
At 30 September 2021	<u>1</u>
NET BOOK VALUE	
At 30 September 2021	<u><u>1</u></u>

The Group or the Company's investments at the Statement of Financial Position date in the share capital of companies include the following:

Subsidiary

Medical Devices UK Leasing Limited
Registered office: United Kingdom
Nature of business: Leasing of machinery

	%
Class of shares:	holding
Ordinary	100.00

Medical Devices UK Leasing Limited benefits from exemption from audit as a result of the issue of a parental guarantee under Section 479A of Companies Act 2006.

15. INVENTORIES

	Group	
	2021	2020 as restated
	£	£
Finished goods	<u>24,796</u>	<u>-</u>

16. TRADE AND OTHER RECEIVABLES

	Group		Company	
	2021	2020 as restated	2021	2020 as restated
	£	£	£	£
Current:				
Trade debtors	227,240	161,845	164,814	161,845
Amounts owed by related party	1,117,821	1,065,591	1,117,821	1,065,591
Other debtors	90,271	128,392	90,271	128,392
VAT	37,557	-	-	-
Prepayments and accrued income	<u>170,287</u>	<u>293,051</u>	<u>168,954</u>	<u>293,051</u>
	<u><u>1,643,176</u></u>	<u><u>1,648,879</u></u>	<u><u>1,541,860</u></u>	<u><u>1,648,879</u></u>

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 30 SEPTEMBER 2021

16. TRADE AND OTHER RECEIVABLES - continued

Fair value of trade receivables

The directors consider that the carrying amount of trade and other receivables is approximately equal to their fair value.

No significant receivable balances are impaired at the reporting end date.

17. CASH AND CASH EQUIVALENTS

	Group		Company	
	2021	2020	2021	2020
	£	as restated £	£	as restated £
Bank accounts	<u>3,971,056</u>	<u>2,458,121</u>	<u>3,829,059</u>	<u>2,458,121</u>

18. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:

Number:	Class:	Nominal value:	2021	2020
			£	as restated £
14,118	Ordinary	10p	<u>1,412</u>	<u>1,412</u>

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 30 SEPTEMBER 2021

19. RESERVES

Group	Retained	Share	Totals
	earnings £	premium £	£
At 1 October 2020	22,632	2,946,853	2,969,485
Prior year adjustment	<u>(52,143)</u>		<u>(52,143)</u>
Deficit for the year	<u>(29,511)</u> <u>(378,263)</u>		<u>2,917,342</u> <u>(378,263)</u>
At 30 September 2021	<u>(407,774)</u>	<u>2,946,853</u>	<u>2,539,079</u>
Company			
	Retained	Share	Totals
	earnings £	premium £	£
At 1 October 2020	22,632	2,946,853	2,969,485
Prior year adjustment	<u>(52,143)</u>		<u>(52,143)</u>
Deficit for the year	<u>(29,511)</u> <u>(727,363)</u>		<u>2,917,342</u> <u>(727,363)</u>
At 30 September 2021	<u>(756,874)</u>	<u>2,946,853</u>	<u>2,189,979</u>

Retained earnings

The Retained earnings reserve represents the cumulative profits and losses, net of any distributions to the Company's shareholders.

Share premium

The share premium reserve represents the consideration for shares in excess of their par value.

20. TRADE AND OTHER PAYABLES

	Group		Company	
	2021 £	2020 as restated £	2021 £	2020 as restated £
Current:				
Payments on account	1,036,140	1,305,466	1,036,140	1,305,466
Trade creditors	141,286	24,317	101,312	24,317
Amounts owed to group undertakings	-	-	246,916	-
Social security and other taxes	522,742	509,356	522,742	509,356
Other creditors	120,250	-	-	-
Accruals and deferred income	<u>242,051</u>	<u>266,236</u>	<u>215,851</u>	<u>266,236</u>
	<u>2,062,469</u>	<u>2,105,375</u>	<u>2,122,961</u>	<u>2,105,375</u>

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 30 SEPTEMBER 2021

21. FINANCIAL LIABILITIES - BORROWINGS

	Group		Company	
	2021 £	2020 as restated £	2021 £	2020 as restated £
Current:				
Bank loans	394,100	-	394,100	-
Leases (see note 22)	<u>4,981</u>	<u>190,291</u>	<u>4,981</u>	<u>190,291</u>
	<u>399,081</u>	<u>190,291</u>	<u>399,081</u>	<u>190,291</u>
Non-current:				
Bank loans - 1-5 years	1,837,553	-	1,837,553	-
Leases (see note 22)	<u>-</u>	<u>111,258</u>	<u>-</u>	<u>111,258</u>
	<u>1,837,553</u>	<u>111,258</u>	<u>1,837,553</u>	<u>111,258</u>

Terms and debt repayment schedule

Group

	1 year or less £	1-2 years £	2-5 years £	Totals £
Bank loans	394,100	690,761	1,146,792	2,231,653
Leases	<u>4,981</u>	<u>-</u>	<u>-</u>	<u>4,981</u>
	<u>399,081</u>	<u>690,761</u>	<u>1,146,792</u>	<u>2,236,634</u>

Company

	1 year or less £	1-2 years £	2-5 years £	Totals £
Bank loans	394,100	690,761	1,146,792	2,231,653
Leases	<u>4,981</u>	<u>-</u>	<u>-</u>	<u>4,981</u>
	<u>399,081</u>	<u>690,761</u>	<u>1,146,792</u>	<u>2,236,634</u>

The bank loan is secured by a fixed and floating charge over the Company.

The leases are secured against the assets in which they relate to.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 30 SEPTEMBER 2021

22. LEASING

Group
Right-of-use assets

Property, plant and equipment

	2021	2020
	£	as restated £
COST		
At 1 October 2020	586,722	586,722
Additions	24,000	-
Disposals	<u>(473,191)</u>	<u>-</u>
	<u>137,531</u>	<u>586,722</u>
DEPRECIATION		
At 1 October 2020	294,449	84,369
Charge for year	193,810	210,080
Eliminated on disposal	<u>(387,870)</u>	<u>-</u>
	<u>100,389</u>	<u>294,449</u>
NET BOOK VALUE	<u>37,142</u>	<u>292,273</u>

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 30 SEPTEMBER 2021

Company
Right-of-use assets

Property, plant and equipment

	2021	2020 as restated
	£	£
COST		
At 1 October 2020	586,722	586,722
Additions	24,000	-
Disposals	<u>(473,191)</u>	<u>-</u>
	<u>137,531</u>	<u>586,722</u>
DEPRECIATION		
At 1 October 2020	294,449	84,369
Charge for year	193,810	210,080
Eliminated on disposal	<u>(387,870)</u>	<u>-</u>
	<u>100,389</u>	<u>294,449</u>
NET BOOK VALUE	<u>37,142</u>	<u>292,273</u>

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 30 SEPTEMBER 2021

22. LEASING - continued

Group
Lease liabilities

Minimum lease payments fall due as follows:

	2021	2020 as restated
	£	£
Gross obligations repayable:		
Within one year	5,030	199,286
Between one and five years	-	113,452
	<u>5,030</u>	<u>312,738</u>
Finance charges repayable:		
Within one year	49	8,995
Between one and five years	-	2,194
	<u>49</u>	<u>11,189</u>
Net obligations repayable:		
Within one year	4,981	190,291
Between one and five years	-	111,258
	<u>4,981</u>	<u>301,549</u>

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 30 SEPTEMBER 2021

22. LEASING - continued

Company
Lease liabilities

Minimum lease payments fall due as follows:

	2021	2020 as restated
	£	£
Gross obligations repayable:		
Within one year	5,030	199,286
Between one and five years	-	113,452
	<u>5,030</u>	<u>312,738</u>
Finance charges repayable:		
Within one year	49	8,995
Between one and five years	<u>-</u>	<u>2,194</u>
	<u>49</u>	<u>11,189</u>
Net obligations repayable:		
Within one year	4,981	190,291
Between one and five years	<u>-</u>	<u>111,258</u>
	<u>4,981</u>	<u>301,549</u>

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 30 SEPTEMBER 2021

23. FINANCIAL INSTRUMENTS

The following table shows the carrying amounts and fair values of financial assets and financial liabilities, including their level in the fair value hierarchy.

The fair values of all financial assets and financial liabilities by class together with their carrying amounts shown in the balance sheet are as follows:

	2021 £	2020 £
<u>Financial assets at amortised costs</u>		
Financial assets at amortised cost	1,902,060	1,564,337
Cash and cash equivalents	3,971,056	2,458,121
<u>Financial assets at fair value through profit or loss</u>	-	-
	<u>5,873,116</u>	<u>4,022,458</u>
	2021 £	2020 £
<u>Liabilities at amortised cost</u>		
Trade and other payables	1,375,623	747,766
Borrowings	2,236,634	301,549
	<u>3,612,257</u>	<u>1,049,315</u>

The carrying amounts of cash and bank balances, trade and other receivables, trade and other payables and amounts due to and from related parties approximate their fair values because these are short term in nature. Such items have been classified as under amortised cost in the above table.

Measurement of fair values

The fair value of financial assets and financial liabilities are included at the amount at which the instruments could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale. The following methods and assumptions were used to estimate the fair values:

- Financial liabilities at amortised cost approximate their carrying amounts either due to their short-term maturities or because they are floating rate instruments that are repriced to market interest rates on or near the end of the reporting period.
- The fair value of unquoted debt securities is determined by reference to portfolio statements provided by third party fund managers. The appropriateness of the valuation methodologies and assumptions adopted are reviewed along with the appropriateness and reliability of the inputs used in the valuations by management.
- Significant changes in fair value measurements from period to period are evaluated for reasonableness. Key drivers of the changes are identified and assessed for reasonableness against relevant information from independent sources, or internal sources if necessary and appropriate.

The Group uses the following hierarchy for determining and disclosing the fair value of financial instruments by valuation techniques:

- Level 1 - quoted prices (unadjusted) in active markets for identical assets or liabilities that the Group can access at the measurement date;
- Level 2 - inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 30 SEPTEMBER 2021

Level 3 - unobservable inputs for the asset or liability.

Financial risk management

The Group has exposure to the following risks arising from financial instruments:

- Credit Risk
- Liquidity risk
- Market risk
- Currency risk

Risk management framework

Credit risk

Financial risk management:

Credit risk refers to the risk of default on its obligation by the counterparty resulting in a financial loss. The carrying amount of financial assets represents the maximum credit risk exposure at the reporting date. Trade receivables and unbilled revenue, if any are typically unsecured and are derived from revenue earned from customers. Credit risk has always been managed by the group through credit approvals, establishing credit limits and continuously monitoring the creditworthiness of customers to which the Group grants credit terms in the normal course of business. The Group uses expected credit loss model to assess the impairment loss or gain. The Group uses a provision matrix to compute the expected credit loss allowance for trade receivables. The provision matrix takes into account available external and internal credit risk factors.

Trade receivables and loans:

The Group's exposure to credit risk is influenced mainly by the individual characteristics of each customer. Trade receivables and unbilled revenue are typically unsecured and are derived from revenue earned from external customers. Credit risk has always been managed by the Group through credit approvals, establishing credit limits and continuously monitoring the creditworthiness of customers to which the Group grants credit terms in the normal course of business.

On account of adoption of IFRS9, the Group uses an expected credit loss model to assess the impairment loss or gain. The Group has used a simplified approach for its trade receivables and other receivables to compute loss allowance. Credit risk is managed through credit approvals, establishing credit limits and continuously monitoring the creditworthiness of customers to which the Group grants credit terms in the normal course of business. The Group establishes an allowance for doubtful debts and impairment that represents its estimate of incurred losses in respect of the Group's trade receivables, certain loans and advances and other financial assets.

No single customer accounted for more than 10% of the trade receivables as of 30 September 2021 and as such, there is no significant concentration of credit risk.

Cash and bank balances (includes amounts classified under other bank balances and deposits and other receivables).

The Company holds cash and bank balances of £3,971,056 at 30 September 2021 (2020: £2,458,121). The Company holds cash and cash equivalents with credit worthy banks and financial institutions as at the reporting dates which has been measured on the 12-month expected loss basis. The credit worthiness of such banks and financial institutions are evaluated by the management on an ongoing basis and is considered to be good with low credit risk.

Market risk

Financial risk management:

Market risk is the risk that changes in market prices, such as foreign exchange rates and interest rates that can affect the Group's income or the value in its holdings of financial instruments

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 30 SEPTEMBER 2021**

The Group does undertake hedge accounting as many of its transactions are made in a currency that is the functional currency of the related subsidiary entity and so there is a natural economic hedge present.

Foreign currency risk:

The Group's exposure to foreign currency risk is as follows. This is based on the carrying amount for monetary financial instruments:

Currency risk

Foreign exchange risk arises from a change in foreign currency exchange rate, which is expected to have an adverse effect on the Group in the current reporting period and in future years. The Group operates in several countries and subsidiary, associated and joint venture companies within the Group maintain their books and records in their respective functional currencies. The Group's accounting policy is to translate the results of overseas subsidiary companies using the weighted average exchange rates. Net assets denominated in foreign currencies and held at the financial year end are translated into Pounds Sterling, the Group's reporting currency, at year end exchange rates. Fluctuations in the exchange rate between the functional currencies and Pounds Sterling will therefore have an impact on the Group. It is the Group's policy not to hedge exposures arising from such translations. The Group's strategy is to fund overseas operations with borrowings denominated in their functional currencies as a natural hedge against overseas assets.

24. PENSION COMMITMENTS

The Group operates a defined contribution pension scheme for all qualifying employees. The assets of the scheme are held separately from those of the Group in an independently administered fund. The total charge for the year in respect of the defined contribution plan is £59,556 (2020: £52,863).

25. SHARE-BASED PAYMENT TRANSACTIONS

During the year, no options over £0.1B shares in the Company (2020: 2,575,000) were granted to employees. The total number of £0.1B shares under options at the year end amounted to 2,575,000 (2020: 2,575,000).

The fair value of the share options is considered to be immaterial to the group and on this basis the directors have not recognised a charge in the profit or loss for share based payments.

26. RELATED PARTY DISCLOSURES

At the year end date, the Group was owed £1,117,821 (2020: £1,065,591) by Medical Management Systems LLC, a company incorporated in Delaware and related to the members of this Company. Interest of £51,252 (2020 £30,030) was received in connection with this loan.

27. ULTIMATE CONTROLLING PARTY

The Group was under the control of D W Temple during the current and the preceding financial year.